Issue: June 2017
June 19, 2017
1 min read

Familial Chylomicronemia Syndrome: Cause, Effect, and Solutions to Improve Patients’ Quality-of-Life

Issue: June 2017
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

Familial chylomicronemia syndrome (FCS) is a rare and potentially life-threatening genetic disease. The clinical hallmark of FCS is pancreatitis associated with marked chylomicronemia and triglyceridemia. It is important that gastroenterologists recognize the signs and symptoms to properly evaluate, as well as manage, patients with FCS. In this activity, a gastroenterologist will review the diagnosis, assessment, management, ongoing challenges, and future therapeutic options for patients with FCS.

Purpose/Learning Objectives:

Upon successful completion of this educational activity, participants should be better able to:

  • Assess the burden of FCS, its pathophysiology, and the importance of early diagnosis and treatment.
  • Describe the clinical symptomatology associated with FCS, as well as diagnostic modalities that assist in earlier diagnosis.
  • Evaluate the use of dietary modifications for the management of FCS based on efficacy and impact on patient quality-of-life.
  • Recognize the benefits and limitations of available and emerging therapeutic interventions for the management of FCS.

Click here to see this Education Lab Activity.


Author(s)/Faculty: Andres Gelrud, MD, MMSc
Source: Healio Gastroenterology Education Lab
Type: Lecture
Articles/Items: 4
Release Date: 5/16/2017
Expiration Date: 5/15/2018
Credit Type: CME/CNE/CPE
Number of Credits: 1
Cost: Free
Provider: Vindico Medical Education

CME Information

Sponsorship Statement: This continuing medical education activity is provided by Vindico Medical Education.

Support Statement: This activity is supported by an educational grant from Akcea Therapeutics, a subsidiary of Ionis Pharmaceuticals Inc. and endorsed by The National Pancreas Foundation.

Target Audience: The intended audience for the activity is gastroenterologists, pancreatologists, and other health care professionals involved in the treatment of patients with familial chylomicronemia syndrome (FCS).